We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...
In a Monday interview with CNBC’s Jim Cramer, Papa John’s CEO Todd Penegor described how the pizza franchise tweaked its ...
The exorbitant costs of drugs like Wegovy — especially compared to other countries — have prompted some insurers to tighten ...
Even a little weight loss can work wonders for your health. A study found that people at high risk for developing type 2 diabetes who lost 5-7% of their weight had a 58% lower risk of developing it.
FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...
Another pressing concern for participants was the rise in drug costs, with 54% expecting at least half of U.S. states to establish drug-affordability boards. Additionally, 97% foresee a 25% surge in ...
Medications like Ozempic and Mounjaro work by mimicking naturally occurring hormones in the body, such as glucagon-like ...
Two new class action complaints, both captioned Robins v. Lemme Inc., were filed in in California Superior Court and the Southern District of New ...
“Whether consumers are using GLP-1 medications for weight management or are reducing sugar intake as part of their overall ...
A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...
The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...
Amid the soaring use of glucagon-like peptide-1 (GLP-1) drugs for intentional weight loss, a vastly different movement appears to be gaining traction in health care: Many clinicians are pushing for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results